中国药业2025，Vol.34Issue(8)：119-123,5.DOI:10.3969/j.issn.1006-4931.2025.08.028
伏诺拉生致不良反应文献分析
Literature Analysis of Adverse Drug Reactions Induced by Vonoprazan
摘要
Abstract
Objective To provide a reference for safe clinical medication of vonoprazan.Methods The case reports of ADRs induced by vonoprazan in the CNKI,WanFang,VIP,Web of Science,PubMed and Embase from the inception of these databases to February 2024 were searched,and the occurrence characteristics of corresponding ADRs were counted and analyzed.Results A total of seventeen literatures were collected with one for Chinese and sixteen for English,enrolled 24 cases and 54 case times.The earliest case reported in 2017,most cases reported in Japan(23 cases,95.83%)and most cases reported in 2021(10 cases,41.67%).Among the patients,there were 13 males(54.17%)and 11 females(45.83%),their average age was(68.96±12.77)years with most patients over 60 years old(70.83%).The primary disease of patients was mainly gastroesophageal reflux disease(10 cases,41.67%),and the comorbidity of patients was mainly infection with Helicobacter pylori(8 cases).The medication regimen of 20 mg/d(12 cases)was more common,and 9 cases(37.50%)had combination therapy.ADRs mainly occurred from 3 days to 4 years,mostly concentrating within 6 months after administration(14 case times,58.33%).ADRs mainly involved the gastrointestinal system(35 case times,64.81%),and mainly manifested as gastrin levels elevated(14 case times,25.93%),followed by redness of gastric mucosa(8 case times,14.81%).21 patients recovered or got improved after discontinuation of medication and/or treatment except that 3 patients had unknown prognosis.Conclusion T he ADRs induced by voporazan involve multiple organs/systems.It is necessary to strengthen drug monitoring,timely discovery and proactive handling of ADRs in time so as to ensure the safety of patients.关键词
伏诺拉唑/药品不良反应/文献分析/用药安全Key words
vonoprazan/adverse drug reaction/literature analysis/medication safety分类
医药卫生引用本文复制引用
岳小飞,王璐,王中华,杨占江..伏诺拉生致不良反应文献分析[J].中国药业,2025,34(8):119-123,5.基金项目
国家自然科学基金[81803483]. （）
